Skip to main content

Advertisement

SpringerLink
Log in

Health Care-Associated Infective Endocarditis: a Growing Entity that Can Be Prevented

  • Cardiovascular Infections (D Levine, Section Editor)
  • Published:
Current Infectious Disease Reports Aims and scope Submit manuscript

Abstract

Infective endocarditis (IE) continues to be a serious disease with a poor prognosis and high mortality. Neither incidence rates nor mortality have decreased in recent decades. Because of this, it is important to prevent IE in patients at risk. In the past, prevention of IE has focused on antimicrobial prophylaxis, mainly for dental procedures. However, recent major changes in epidemiology, the most significant being the growing frequency and high mortality rate of health care-associated valve endocarditis (HAIE), mean that preventive strategies against IE must also change. Since intravascular catheters are the most common source of bacteremia among patients with HAIE, significant efforts must be made to minimize the risk of catheter-related bloodstream infections. Measures for preventing the infection of prosthetic valves and cardiac implantable devices at the time of implantation also need to be implemented.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Murdoch DR, Corey GR, Hoen B, Miró JM, Fowler Jr VG, Bayer AS, et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis—Prospective Cohort Study. Arch Intern Med. 2009;169:463–73.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Sy RW, Kritharides L. Health care exposure and age in infective endocarditis: results of a contemporary population based profile of 1536 patients in Australia. Eur Heart J. 2010;31:1890–7.

    Article  PubMed  Google Scholar 

  3. de Sa DD C, Tleyjeh IM, Anavekar NS, et al. Epidemiological trends of infective endocarditis: a population-based study in Olmsted County, Minnesota. Mayo Clin Proc. 2010;85:422–6.

    Article  PubMed Central  Google Scholar 

  4. Fedeli U, Schievano E, Buonfrate D, Pellizzer G, Spolaore P. Increasing incidence and mortality of infective endocarditis: a population-based study through a record-linkage system. BMC Infect Dis. 2011;11:48.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Duval X, Delahaye F, Alla F, et al. Temporal trends in infective endocarditis in the context of prophylaxis guideline modifications: three successive population-based surveys. J Am Coll Cardiol. 2012;59:1968–76.

    Article  PubMed  Google Scholar 

  6. Federspiel JJ, Stearns SC, Peppercorn AF, Chu VH, Fowler Jr VG. Increasing US rates of endocarditis with Staphylococcus aureus: 1999–2008. Arch Intern Med. 2012;172:363–5.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Selton-Suty C, Iung B, Alla F, Célard M, Strady C, Duval X, et al. Preeminence of Staphylococcus aureus in infective endocarditis: a 1-year population-based survey. Clin Infect Dis. 2012;54:1230–9.

    Article  PubMed  Google Scholar 

  8. Mylonakis E, Calderwood SB. Infective endocarditis in adults. N Engl J Med. 2001;345:1318–30.

    Article  PubMed  CAS  Google Scholar 

  9. Thuny F, Grisoli D, Collart F, Habib G, Raoult D. Management of infective endocarditis: challenges and perspectives. Lancet. 2012;379:965–75.

    Article  PubMed  Google Scholar 

  10. Hoen B, Duval X. Infective endocarditis. N Engl J Med. 2013;368:1425–33.

    Article  PubMed  CAS  Google Scholar 

  11. Moreillon P, Que YA. Infective endocarditis. Lancet. 2004;363:139–49.

    Article  PubMed  Google Scholar 

  12. Slipczuck L, Nicolas Codolosa J, Davila CD, Romero-Corrl A, Yung J, Pressman GS, et al. Infective endocarditis epidemiology over five decades: a systematic review. Plos ONE. 2013;8:e82665.

    Article  Google Scholar 

  13. Prendergast BD. The changing face of infective endocarditis. Heart. 2006;92:879–85.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  14. Yew HS, Murdoch DR. Global trends in infective endocarditis epidemiology. Cur Infect Dis Rep. 2012;14:367–72.

    Article  Google Scholar 

  15. Ferreiros E, Nacinovich F, Casabé JH, et al. Epidemiological, clinical and microbiologic profile of infective endocarditis in Argentina: a national survey. The Endocarditis Infecciosa en la República Argentina-2 (EIRA-2) Study. Am Heart J. 2006;151:545–52.

    Article  PubMed  Google Scholar 

  16. Tleyjeh IM, Abdel-Latif A, Rahbi H, Scott CG, Bailey KR, Steckelberg JM, et al. A systematic review of population-based studies of infective endocarditis. Chest. 2007;132:1025–35.

    Article  PubMed  Google Scholar 

  17. Cabell CH, Heidenreich PA, Chu VH, et al. Increasing rates of cardiac device infections among Medicare beneficiaries: 1990–1999. Am Heart J. 2004;147:582–6.

    Article  PubMed  Google Scholar 

  18. Voigt A, Shalaby A, Saba S. Rising rates of cardiac rhythm management device infections in the United States: 1996 through 2003. J Am Coll Cardiol. 2006;48:590–1.

    Article  PubMed  Google Scholar 

  19. Voigt A, Shalaby A, Saba S. Continued rise in rates of cardiovascular implantable electronic device infections in the United States: temporal trends and causative insights. Pacing Clin Electrophysiol. 2010;33:414–9.

    Article  PubMed  Google Scholar 

  20. Greenspon AJ, Patel JD, Lau E, et al. 16-Year trends in the infection burden for pacemakers and implantable cardioverter defibrillators in the United States 1993 to 2008. J Am Coll Cardiol. 2011;58:1001–6.

    Article  PubMed  Google Scholar 

  21. Benito N, Miro JM, de Lazzari E, et al. Health care-associated native valve endocarditis: importance of non-nosocomial acquisition. Ann Intern Med. 2009;150:586–94.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Thuny F, Avierinos JF, Habib G. Changing patterns in epidemiological profiles and prevention strategies in infective endocarditis: from teeth to healthcare-related infection. Eur Heart J. 2010;31:1826–187.

    Article  PubMed  Google Scholar 

  23. Lomas JM, Martinez-Marcos FJ, Plata A, et al. Healthcare-associated infective endocarditis: an undesirable effect of healthcare universalization. Clin Microbiol Infect. 2010;16:1683–90.

    Article  PubMed  CAS  Google Scholar 

  24. Siegman-Igra Y, Koifman B, Porat R, Porat D, Giladi M. Healthcare associated enfective endocarditis: a distinct entity. Scand J Infect Dis. 2008;40:474–80.

    Article  PubMed  Google Scholar 

  25. Fernández-Fidalgo N, Almirante B, Tornos P, Pigrau C, Sambola A, Igual A, et al. Contemporaty epidemiology and prognosis of health care-associated infective endocarditis. Clin Infect Dis. 2008;47:1287–97.

    Article  Google Scholar 

  26. Wang A, Athan E, Pappas PA, Fowler Jr VG, Olaison L, Paré C, et al. Contemporary clinical profile and outcome of prosthetic valve endocarditis. JAMA. 2007;297:1354–61.

    Article  PubMed  CAS  Google Scholar 

  27. Athan E, Chu VH, Tattevin P, Selton-Suty C, Jones P, Naber C, et al. Clinical characteristics and outcome of infective endocarditis involving implantable cardiac devices. JAMA. 2012;307:1727–35.

    Article  PubMed  CAS  Google Scholar 

  28. Fowler Jr VG, Miro JM, Hoen B, Cabell CH, Abrutyn E, Rubinstein E, et al. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA. 2005;293:3012–21.

    Article  PubMed  CAS  Google Scholar 

  29. Fernández-Guerrero ML, Goyenechea A, Verdejo C, Roblas R, de Górgolas M. Enterococcal endocarditis on native and prosthetic valves. A review of clinical and prognostic factors with emphasis on hospital-acquired infections as a major determinant of outcome. Medicine. 2007;86:363–77.

    Article  PubMed  Google Scholar 

  30. Martín-Dávila P, Fortún J, Navas E, Cobo J, Jiménez-Mena M, Moya JL, et al. Nosocomial endocarditis in a tertiary hospital. An increasing trend in native valve cases. Chest. 2005;128:772–9.

    Article  PubMed  Google Scholar 

  31. Lamas CC, Eykyn SJ. Hospital acquired native valve endocarditis analysis of 22 cases presenting over 11 years. Heart. 1998;79:442–7.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  32. Fernández-Guerrero ML, Verdejo C, Azofra J, de Górgolas M. Hospital-acquired infectious endocarditis not associated with cardiac surgery: an emerging problem. Clin Infect Dis. 1995;20:16–23.

    Article  PubMed  Google Scholar 

  33. Nucifora G, Badano LP, Viale P, Gianfagna P, Allocca G, Montanaro D, et al. Infective endocarditis in chronic haemodialysis patients: an increasing clinical challenge. Eur Heart J. 2007;28:2307–12.

    Article  PubMed  Google Scholar 

  34. Giamarellou H. Nosocomial cardiac infections. J Hosp Infec. 2002;50:91–105.

    Article  CAS  Google Scholar 

  35. Baddour LM, Cha Y, Wilson WR. Infections of cardiovascular implantable electronic devices. N Engl J Med. 2012;367:842–9.

    Article  PubMed  CAS  Google Scholar 

  36. Sohail MR, Uslan DZ, Khan AH, et al. Risk factor analysis of permanent pacemaker infection. Clin Infect Dis. 2007;45:166–73.

    Article  PubMed  Google Scholar 

  37. Pronovost P, Needham D, Berenholtz S, et al. An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med. 2006;355:2725.

    Article  PubMed  CAS  Google Scholar 

  38. O’Grady NP, Alexander M, Burns LA, Dellinger EP, Garland J, Heard SO, et al. Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis. 2011;52:e162–93.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Schiffer CA, Mangu PB, Wade JC, Camp-Sorrell D, Cope DG, El-Rayes BF, et al. Central venous catheter care for the patient with cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2013;31:1357–70.

    Article  PubMed  Google Scholar 

  40. Marschall J, Mermel LA, Fakih M, Hadaway L, Kallen A, O’Grady NP, et al. Strategies to prevent central line-associated bloodstream infections in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol. 2014;35:753–71.

    Article  PubMed  Google Scholar 

  41. Ge X, Cavallazzi R, Li C, Pan SM, Wang YW, Wang FL. Central venous access sites for the prevention of venous thrombosis, stenosis and infection. Cochrane Database Syst Rev. 2012 Mar 14; 3: CD004084.

  42. Lorente L, Henry C, Martín MM, Jiménez A, Mora ML. Central venous catheter-related infection in a prospective and observational study of 2,595 catheters. Crit Care. 2005;9:R631–5.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Parienti JJ, du Cheyron D, Timsit JF, Traoré O, Kalfon P, Mimoz O, et al. Meta-analysis of subclavian insertion and nontunneled central venous catheter-associated infection risk reduction in critically ill adults. Crit Care Med. 2012;40:1627–34.

    Article  PubMed  Google Scholar 

  44. Marik PE, Flemmer M, Harrison W. The risk of catheter-related bloodstream infection with femoral venous catheters as compared to subclavian and internal jugular venous catheters: a systematic review of the literature and meta-analysis. Crit Care Med. 2012;40:2479–85.

    Article  PubMed  Google Scholar 

  45. Deshpande KS, Hatem C, Ulrich HL, Currie BP, Aldrich TK, Bryan-Brown CW, et al. The incidence of infectious complications of central venous catheters at the subclavian, internal jugular, and femoral sites in an intensive care unit population. Crit Care Med. 2005;33:13–20.

    Article  PubMed  Google Scholar 

  46. Chaiyakunapruk N, Veenstra DL, Lipsky BA, Saint S. Chlorhexidine compared with povidone-iodine solution for vascular catheter-site care: a meta-analysis. Ann Intern Med. 2002;136:792–801.

    Article  PubMed  CAS  Google Scholar 

  47. Mimoz O, Villeminey S, Ragot S, Dahyot-Fizelier C, Laksiri L, Petitpas F, et al. Chlorhexidine-based antiseptic solution vs alcohol-based povidone-iodine for central venous catheter care. Arch Intern Med. 2007;22(167):2066–72.

    Article  Google Scholar 

  48. Safdar N, O’Horo JC, Ghufran A, Bearden A, Didier ME, Chateau D, et al. Chlorhexidine-impregnated dressing for prevention of catheter-related bloodstream infection: a meta-analysis. Crit Care Med. 2014;42:1703–13.

    Article  PubMed  CAS  Google Scholar 

  49. James MT, Conley J, Tonelli M, Manns BJ, MacRae J, Hemmelgarn BR, et al. Meta-analysis: antibiotics for prophylaxis against hemodialysis catheter-related infections. Ann Intern Med. 2008;148:596–605.

    Article  PubMed  Google Scholar 

  50. O’Horo JC, Silva GL, Munoz-Price LS, Safdar N. The efficacy of daily bathing with chlorhexidine for reducing healthcare-associated bloodstream infections: a meta-analysis. Infect Control Hosp Epidemiol. 2012;33:257–67.

    Article  PubMed  Google Scholar 

  51. Wang H, Huang T, Jing J, et al. Effectiveness of different central venous catheters for catheter-related infections: a network meta-analysis. J Hosp Infect. 2010;76:1–11.

    Article  PubMed  CAS  Google Scholar 

  52. Casey AL, Mermel LA, Nightingale P, Elliott TS. Antimicrobial central venous catheters in adults: a systematic review and meta-analysis. Lancet Infect Dis. 2008;8:763.

    Article  PubMed  CAS  Google Scholar 

  53. Blot K, Bergs J, Vogelaers D, Blot S, Vandijck D. Prevention of central line-associated bloodstream infections through quality improvement interventions: a systematic review and meta-analysis. Clin Infect Dis 2014 (in press).

  54. Pronovost PJ, Berenholtz SM, Goeschel CA, et al. Creating high reliability in health care organizations. Health Serv Res. 2006;41:1599–617.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Duval X, Leport C. Prophylaxis of infective endocarditis: current tendencies, continuing controversies. Lancet Infect Dis. 2008;8:225–32.

    Article  PubMed  CAS  Google Scholar 

  56. Falces C, Miró JM. Prevention of infective endocarditis: between progress in scientific knowledge and the lack of randomized trials. Rev Esp Cardiol. 2012;65:1072–4.

    Article  PubMed  Google Scholar 

  57. Wilson W, Taubert K, Gewitz M, Lockhart P, Baddour L, Levison M, et al. Prevention of infective endocarditis. Guidelines from the American Heart Association. Circulation. 2007;116:1736–54.

    Article  PubMed  Google Scholar 

  58. Nishimura RA, Carabello BA, Faxon DP, et al. ACC/AHA 2008 guideline update on valvular heart disease: focused update on infective endocarditis: a report of the American College of Cardiology/American Heart Association task force on practice guidelines: endorsed by the society of cardiovascular anesthesiologists, society for cardiovascular angiography and interventions, and society of thoracic surgeons. Circulation. 2008;118:887–96.

    Article  PubMed  Google Scholar 

  59. Habib G, Hoen B, Tornos P, Thuny F, Prendergast B, Vilacosta I, et al. The Task Force on the prevention, diagnosis and treatment of infective endocarditis of the European Society of Cardiology. Guidelines on the prevention, diagnosis and treatment of infective endocarditis. Eur Heart J. 2009;30:2369–413.

    Article  PubMed  Google Scholar 

  60. Centre for Clinical Practice at NICE (UK). Prophylaxis against infective endocarditis: antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures. London: National Institute for Health and Clinical Excellence (UK); 2008 [accessed 20 Jun 2014]. Available at: http://guidance.nice.org.uk/cg64.

  61. Thornhill MH, Dayer MJ, Forde JM, Corey GR, Hock G, Chu VH, et al. Impact of the NICE guideline recommending cessation of antibiotic prophylaxis for prevention of infective endocarditis: before and after study. BMJ. 2011;342:342–d2392.

    Article  Google Scholar 

  62. Karchmer AW, Longworth DL. Infections of intracardiac devices. Infect Dis Clin N Am. 2002;16:477–505.

    Article  Google Scholar 

  63. Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health-Syst Pharm. 2013;70:195–283.

    Article  PubMed  CAS  Google Scholar 

  64. Antimicrobial prophylaxis in surgery. Treatment guidelines from the medical letter 2012;10:73–78.

  65. Wellens F, Pirlet M, Larbuisson R, De Meireleire F, De Sommer P. Prophylaxis in cardiac surgery: a controlled, randomized comparison between cefazolin and cefuroxime. Eur J Cardiothorac Surg. 1995;9:325–9.

    Article  PubMed  CAS  Google Scholar 

  66. Zanetti G, Giardina R, Platt R. Intraoperative redosing of cefazolin and risk for surgical site infection in cardiac surgery. Emerg Infect Dis. 2001;7:828.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  67. De Oliveira JC, Martinelli M, Nishioka SA, Varejao T, Uiepe D, Pedrosa AA, et al. Efficacy of antibiotic prophylaxis before the implantation of pacemakers and cardioverter-defibrillators: results of a large, prospective, randomized, double-blinded, placebo-controlled trial. Circ Arrhythm Electrophysiol. 2009;2:29.

    Article  PubMed  Google Scholar 

  68. Baddour LM, Epstein AE, Erickson CC, Knight BP, Wilson R, Beerman LB, et al. Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. Circulation. 2010;121:458–77.

    Article  PubMed  Google Scholar 

  69. Borer A, Gilad J, Hyam E, et al. Prevention of infections associated with permanent cardiac antiarrhythmic devices by implementation of a comprehensive infection control program. Infect Control Hosp Epidemiol. 2004;25:492–7.

    Article  PubMed  Google Scholar 

  70. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR, Hospital Infection Control Practices Advisory Committee. Guideline for prevention of surgical site infection. Infect Control Hosp Epidemiol. 1999;20:250–78.

    Article  PubMed  CAS  Google Scholar 

  71. National Institute for Health and Clinical Excellence (NICE). Surgical site infection: prevention and treatment of surgical site infection. London: NICE, 2008. http://www.nice.org.uk/guidance/cg74/resources/guidance-surgical-site-infection-pdf. Accessed 26 Juny 2014.

  72. Alexander JW, Solomkin JS, Edwards MJ. Updated recommendations for control of surgical site infections. Ann Surg. 2011;253:1082–93.

    Article  PubMed  Google Scholar 

  73. Anderson DJ, Podgorny K, Berríos-Torres SI, Bratzler DW, Dellinger EP, Greene L, et al. Strategies to prevent surgical site infections in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol. 2014;35:605–27.

    Article  PubMed  Google Scholar 

  74. Perl TM, Cullen JJ, Wenzel RP, et al. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med. 2002;346:1871–7.

    Article  PubMed  CAS  Google Scholar 

  75. Bode LG, Kluytmans JA, Wertheim HF, et al. Preventing surgical-site infections in nasal carriers of Staphylococcus aureus. N Engl J Med. 2010;362:9–17.

    Article  PubMed  CAS  Google Scholar 

  76. Schweizer M, Perencevich E, McDanel J, et al. Effectiveness of a bundled intervention of decolonization and prophylaxis to decrease Gram positive surgical site infections after cardiac or orthopedic surgery: systematic review and meta-analysis. BMJ. 2013;346:f 2743.

    Article  Google Scholar 

  77. Wenzel RP. Minimizing surgical-site infections. N Engl J Med. 2010;362:75–7.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We thank Janet Gaynor Dawson for the help with the English version.

Financial Support

Dr. Juan. M. Pericas held a post-residency Scholarship “Premi Fi de Residència Emili Letang” 2013–14 from the Hospital Clinic, Barcelona, Spain.

Compliance with Ethics Guidelines

ᅟ

Conflict of Interest

Jose M. Miro is a board member for Cubist and Novartis. Miro is a consultant for Abbvie, Bristol-Myers, Squibb, Cubist, Gilead Sciences, Merck, Novartis, Pfizer, and ViiV. Miro has received grants from Cubist, Novartis, NIH, Fondo de Investigaciones Sanitarias, the Spanish Ministry of Health, Spanish Network for AIDS Research, and the Spanish Foundation for AIDS Research and Prevention. Miro received honoraria from Abbott, Boehringer-Ingelheim, Bristol-Myers Squibb, Cubist, Glaxo Smith Kline, Gilead Sciences, Janssen-Cilag, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Schering-Plough, Theravance, and ViiV. Asuncion Moreno, Mercè Gurgui, Juan P. Horcajada, Juan M. Pericas, Natividad Benito, and Francesc Marco have no conflicts of interest. Carlos Mestres works as a consultant for Edwards Lifesciences and has stock in Symetis SA.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the author.

Author information

Authors and Affiliations

  1. Infectious Diseases Unit, Department of Internal Medicine. Hospital de la Santa Creu i Sant Pau—Institut d’Investigació Biomèdica Sant Pau, Universitat Autònoma de Barcelona, Sant Antoni Maria Claret, 167, 08025, Barcelona, Spain

    Natividad Benito & Mercè Gurguí

  2. Spanish Network for the Research in Infectious Diseases (REIPI RD12/0015), Instituto de Salud Carlos III, Madrid, Spain

    Natividad Benito, Mercè Gurguí, Asunción Moreno & José M. Miró

  3. Infectious Diseases Service. Hospital Clínic-IDIBAPS, University of Barcelona, Villarroel, 170, 08036, Barcelona, Spain

    Juan M. Pericas, Asunción Moreno & José M. Miró

  4. Department of Cardiovascular Surgery. Hospital Clínic-IDIBAPS, University of Barcelona, Barcelona, Spain

    Carlos A. Mestres

  5. Servei de Microbiologia. Centre Diagnòstic Biomèdic (CDB). Barcelona Centre for International Health Research (CRESIB), Hospital Clínic-IDIBAPS, University of Barcelona, Barcelona, Spain

    Francesc Marco

  6. Infectious Diseases Service, Hospital del Mar, Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Universitat Pompeu Fabra, Barcelona, Spain

    Juan P. Horcajada

Authors
  1. Natividad Benito
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Juan M. Pericas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mercè Gurguí
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Carlos A. Mestres
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Francesc Marco
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Asunción Moreno
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Juan P. Horcajada
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. José M. Miró
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Natividad Benito or José M. Miró.

Additional information

This article is part of the Topical Collection on Cardiovascular Infections

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Benito, N., Pericas, J.M., Gurguí, M. et al. Health Care-Associated Infective Endocarditis: a Growing Entity that Can Be Prevented. Curr Infect Dis Rep 16, 439 (2014). https://doi.org/10.1007/s11908-014-0439-4

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11908-014-0439-4

Keywords

Search

Navigation